1. Home
  2. KPTI vs KOPN Comparison

KPTI vs KOPN Comparison

Compare KPTI & KOPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KPTI
  • KOPN
  • Stock Information
  • Founded
  • KPTI 2008
  • KOPN 1984
  • Country
  • KPTI United States
  • KOPN United States
  • Employees
  • KPTI N/A
  • KOPN 144
  • Industry
  • KPTI Biotechnology: Pharmaceutical Preparations
  • KOPN Semiconductors
  • Sector
  • KPTI Health Care
  • KOPN Technology
  • Exchange
  • KPTI Nasdaq
  • KOPN Nasdaq
  • Market Cap
  • KPTI 81.1M
  • KOPN 277.5M
  • IPO Year
  • KPTI 2013
  • KOPN 1992
  • Fundamental
  • Price
  • KPTI $0.63
  • KOPN $1.82
  • Analyst Decision
  • KPTI Strong Buy
  • KOPN Strong Buy
  • Analyst Count
  • KPTI 4
  • KOPN 4
  • Target Price
  • KPTI $5.00
  • KOPN $2.63
  • AVG Volume (30 Days)
  • KPTI 694.6K
  • KOPN 10.3M
  • Earning Date
  • KPTI 02-27-2025
  • KOPN 03-13-2025
  • Dividend Yield
  • KPTI N/A
  • KOPN N/A
  • EPS Growth
  • KPTI N/A
  • KOPN N/A
  • EPS
  • KPTI N/A
  • KOPN N/A
  • Revenue
  • KPTI $148,442,000.00
  • KOPN $44,266,305.00
  • Revenue This Year
  • KPTI $5.47
  • KOPN $21.18
  • Revenue Next Year
  • KPTI $6.33
  • KOPN $13.57
  • P/E Ratio
  • KPTI N/A
  • KOPN N/A
  • Revenue Growth
  • KPTI 1.77
  • KOPN 0.60
  • 52 Week Low
  • KPTI $0.58
  • KOPN $0.56
  • 52 Week High
  • KPTI $1.70
  • KOPN $2.82
  • Technical
  • Relative Strength Index (RSI)
  • KPTI 46.51
  • KOPN 61.10
  • Support Level
  • KPTI $0.60
  • KOPN $1.57
  • Resistance Level
  • KPTI $0.70
  • KOPN $1.99
  • Average True Range (ATR)
  • KPTI 0.05
  • KOPN 0.21
  • MACD
  • KPTI -0.00
  • KOPN 0.02
  • Stochastic Oscillator
  • KPTI 46.61
  • KOPN 69.23

About KPTI Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

About KOPN Kopin Corporation

Kopin Corp is a provider of high-performance application-specific optical solutions consisting of high-resolution microdisplays and optics, subassemblies, and headsets. It serves soldiers, avionics, armored vehicles training and simulation military applications, and others. Its product portfolio includes Microdisplays, Spatial Light Modulators, Optical Modules, Medical, Training, and Simulation. Geographically, it derives a majority of its revenue from the Americas and also has a presence in Asia-Pacific; Europe, and Other Countries.

Share on Social Networks: